SIMG
TVTX icon

Stephens Investment Management Group’s Travere Therapeutics TVTX Stock Holding History

Stephens Investment Management Group’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$53.4M Buy
1,798,466
+76,843
+4% +$2.3M 0.73% 58
2025
Q4 		$65.8M Buy
1,721,623
+121,955
+8% +$3.97M 0.86% 48
2025
Q3 		$38.2M Buy
+1,599,668
New +$30.1M 0.5% 90

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Stephens Investment Management Group's TVTX Position: Q1 2026 in Review

Stephens Investment Management Group increased its Travere Therapeutics (TVTX) stake by 4.5% in Q1 2026, buying an estimated $2.3M and bringing the position to 1,798,466 shares worth $53.4M. The position accounts for 0.73% of the portfolio, ranked #58.

Stephens Investment Management Group first reported a position in TVTX in Q3 2025 and has held it in 3 quarters since. The position peaked at $65.8M in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Stephens Investment Management Group held 1,798,466 shares of Travere Therapeutics worth $53.4M as of Q1 2026.
  • Stephens Investment Management Group bought 76,843 Travere Therapeutics shares in Q1 2026, an estimated $2.3M.
  • Travere Therapeutics made up 0.73% of Stephens Investment Management Group's portfolio in Q1 2026, its #58 holding.
  • Stephens Investment Management Group first reported a position in Travere Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Stephens Investment Management Group's Travere Therapeutics position peaked at $65.8M in Q4 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Stephens Investment Management Group's 13F filing for Q1 2026, filed 28 Apr 2026.